BLTE Belite Bio, Inc
Healthcare$142.01+3.43%ClosedMarket Cap: $5.69B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.10
P/S
0.00
EV/EBITDA
-50.79
DCF Value
$10.53
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.7%
ROA
-11.6%
ROIC
-13.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-32.7M | $-26.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-28.1M | $-25.3M | $— | — |
| FY null | $0.00 | NaN% | $-84.2M | $-77.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-23.0M | $-21.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-17.6M | $-16.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.5M | $-14.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-11.5M | $-10.1M | $— | — |
| FY null | $0.00 | NaN% | $-40.0M | $-36.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-9.7M | $-8.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.5M | $-9.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-8.3M | $-7.9M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-7.0M | $-7.0M | $-0.25 | — |